Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Declines By 35.4%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a significant drop in short interest in June. As of June 30th, there was short interest totalling 16,800 shares, a drop of 35.4% from the June 15th total of 26,000 shares. Based on an average daily trading volume, of 8,400 shares, the short-interest ratio is currently 2.0 days. Approximately 0.2% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Cumberland Pharmaceuticals in a report on Friday, July 5th. They issued a “hold” rating on the stock.

Cumberland Pharmaceuticals Stock Up 3.8 %

Cumberland Pharmaceuticals stock traded up $0.06 during mid-day trading on Friday, hitting $1.50. The company had a trading volume of 3,734 shares, compared to its average volume of 10,283. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.21 and a current ratio of 1.37. Cumberland Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $2.36. The business has a fifty day moving average of $1.52 and a 200 day moving average of $1.76.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 21.67% and a positive return on equity of 0.21%. The company had revenue of $8.50 million during the quarter.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.